Vedolizumab showed no clear difference in serious adverse events compared with placebo (moderate certainty).
Ascorbic acid showed no clear difference in serious adverse events compared with placebo (moderate certainty).
Topiramate 200 to 400 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).
Xiongshao capsule (XSC) plus conventional western medicine (CWM) leads to lower serious adverse events compared with conventional western medicine (CWM) plus placebo (high certainty).
Pregabalin showed no clear difference in serious adverse events compared with placebo at end of treatment (moderate certainty).
It is very uncertain whether ursodeoxycholic acid changes serious adverse events compared with placebo or no intervention (very low certainty).
TDF+ FTC showed no clear difference in serious adverse events compared with placebo (moderate certainty).
TDF showed no clear difference in serious adverse events compared with placebo (moderate certainty).
Febuxostat 80 mg/day showed no clear difference in serious Adverse Events compared with placebo (moderate certainty).
Febuxostat 120 mg/day showed no clear difference in serious Adverse events compared with placebo (moderate certainty).
Febuxostat 40 mg/day probably leads to higher serious Adverse Events compared with placebo (moderate certainty).
GM‐CSF showed no clear difference in serious adverse events compared with placebo (moderate certainty).
Tocilizumab 8 mg/kg + MTX/DMARD showed no clear difference in serious Adverse Events compared with placebo + MTX/DMARD (moderate certainty).
Golimumab 50 mg every 4 weeks + MTX showed no clear difference in serious Adverse Events compared with placebo + MTX (high certainty).
Paracetamol showed no clear difference in serious adverse events: number experiencing 24 weeks compared with placebo (moderate certainty).
Prostaglandin showed no clear difference in serious adverse eventsc ( compared with placebo or standard care (low certainty).
Umeclidinium bromide showed no clear difference in adverse events (not including serious adverse events) compared with placebo (moderate certainty).
Mometasone/formoterol (MF/F) showed no clear difference in adverse events—serious—400/103 Duration of six months compared with placebo (low certainty).
Mometasone/formoterol (MF/F) showed no clear difference in adverse events—serious—200/103 Duration of six months compared with placebo (low certainty).